Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

steriscience pty ltd - pemetrexed disodium, quantity: 551.5 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - pemetrexed disodium, quantity: 110.3 mg - injection, powder for - excipient ingredients: mannitol - malignant pleural mesothelioma. pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer. pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 1102.9 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 551.45 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 110.29 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioorganics b.v. - pemetrexed disodium hemipentahydrate - eq. pemetrexed disodium 1000 mg - powder for concentrate for solution for infusion - 1000 mg - pemetrexed disodium hemipentahydrate - pemetrexed

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioorganics b.v. - pemetrexed disodium hemipentahydrate - eq. pemetrexed disodium 500 mg - powder for concentrate for solution for infusion - 500 mg - pemetrexed disodium hemipentahydrate - pemetrexed

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b-medical b.v. - pemetrexed disodium 604 mg - eq. pemetrexed 500 mg - powder for concentrate for solution for infusion - 500 mg - pemetrexed disodium 604 mg - pemetrexed

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioorganics b.v. - pemetrexed disodium hemipentahydrate - eq. pemetrexed 100 mg - powder for concentrate for solution for infusion - 100 mg - pemetrexed disodium hemipentahydrate - pemetrexed

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide; mannitol; water for injections - malignant pleural mesothelioma:,pemtrex, in combination with cisplatin, is indicated for the treatment of patients with malignant,pleural mesothelioma.,non-small cell lung cancer:,pemtrex in combination with cisplatin is indicated for initial treatment of patients with locally,advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemtrex as monotherapy is indicated for the treatment of patients with locally advanced or,metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior,platinum-based chemotherapy.